(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Collins Foods to offload 20 Taco Bell outlets in Australia - 2Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- 3Illumina unveils dataset to speed up AI-powered drug discovery
- 4Individual Preparation Administrations to Raise Your Wellness Process
- 56 Modest and Strong Tire Brands
- More loons are filling Maine's lakes with their ghostlike calls
- Governments take targeted action as fuel prices hit retail
- The Best 20 Photography Instagram Records to Follow
- Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- Muslim Brotherhood stole half a billion dollars in Gaza donations, Arab sources reveal
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- Israel faces widespread condemnation as NGO ban comes into effect
- 8 Espresso Bean Starting points All over the Planet
- Germany records first wolf bite on human since repopulation
